Results 131 to 140 of about 54,505 (255)

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Volume 78, Issue 6, Page 761-770, June 2026.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source

Benefits and risks of prophylactic glucocorticoids in platinum chemotherapy for extensive-stage small-cell lung cancer: A retrospective study. [PDF]

Mol Clin Oncol
Qingling W, Dafeng W, Yan Z, Xuebo Y.
europepmc   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, Volume 13, Issue 31, 4 June 2026.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

Predictive Value of White Blood Cell Counts for Infection in Patients With Diabetic Ketoacidosis and Rational Use of Antibiotics: A Cross-Sectional Study. [PDF]

Health Sci Rep
Mohammad Aghaei P, Hasannezhad M, Ebrahimi Alavijeh P, Daraei M, Esmaeili S, Salami Khaneshan A, Sohrabi M, Ghaderkhani S.   +7 more
europepmc   +1 more source

Primary Extramedullary Acute Promyelocytic Leukemia Presenting as Cauda Equina Syndrome: A Rare Case Report and Diagnostic Challenge

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT APL presenting as an extramedullary mass is exceedingly rare. Here, we describe extramedullary APL causing cauda equina syndrome, underscoring the diagnostic challenges associated with an atypical presentation, highlighting the complexity of distinguishing extramedullary APL from other conditions, and discussing the stepwise approach to ...
Amir Ali, Marc Ringor, Arbab Khalid, Diana Garcia, Ravishankar Konchada, Ramalingam Ratnasabapathy, Yuna Chae, Arman Melikyan, George Yaghmour   +8 more
wiley   +1 more source

Glucocorticoids as adjunctive therapy for severe myelosuppression induced by combined immune checkpoint inhibitor and chemotherapy: a case report and literature review. [PDF]

Front Oncol
Tang S, Li N, Ma J.
europepmc   +1 more source

Pharmacogenomics of Thiopurine Drugs: A Bench-To-Bedside Success Story in Thailand. [PDF]

Clin Transl Sci
Biswas M, John S, Murad MA, Sukasem C.
europepmc   +1 more source

Pancytopenia With Hypocellular Bone Marrow Revealing Extrahepatic Portal Venous Obstruction and Cavernous Transformation in a Child: A Case Report of a Diagnostic Challenge

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Extrahepatic portal venous obstruction (EHPVO) is a leading cause of prehepatic portal hypertension in children, particularly in developing countries. While upper gastrointestinal bleeding is the most common presentation, EHPVO may rarely manifest predominantly with hematological abnormalities due to hypersplenism, posing a diagnostic ...
Swekchha Adhikari, Aakash Pandit, Melisha Koirala, Biplav Lamichhane, Ram Khadka, Aashish Panta, Shuvra Rimal   +6 more
wiley   +1 more source

Azathioprine Toxicity in Patients With Myasthenia Gravis: A Single Center Experience. [PDF]

Muscle Nerve
Gaini R, Truong T, Morena J.
europepmc   +1 more source

Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions

Cancer, Volume 132, Issue S1, 1 June 2026.
Abstract Antibody–drug conjugates (ADCs) represent a major advance in precision oncology, combining the selectivity of monoclonal antibodies with the cytotoxic potency of chemotherapy. By enabling targeted intracellular delivery of highly potent payloads, ADCs aim to maximize antitumor activity while minimizing systemic toxicity. This review summarizes
André Mansinho, Joana Albuquerque, Andreia Lopes, Emiliano Calvo   +3 more
wiley   +1 more source